Martin Simonetti Email & Phone Number

Scottsdale, Az, Us

Austin, Texas Area

Curtana Pharmaceuticals, founded in 2013, is a privately held, preclinical-stage biopharmaceutical company headquartered in Austin, Texas. In August 2014, the company was awarded a $7.6 million grant from the Cancer Prevention and Research Institute of Texas. Curtana focuses on the development of novel first-in-class, small molecule therapeutics targeting cancer stem cells in the central nervous system for the treatment of glioblastoma and other cancers. Curtana’s OLIG2 inhibitors will be the only adjuvant treatment for nearly all gliomas, including high-grade glioblastomas, which specifically targets the cancer stem cells and is a potent radiosensitizer.

I provide a combination of business development and financial strategy, as well as general management support to emerging, mid-size and large biotechnology companies. I am available to sit on boards based on prior experience on both Nasdaq and NYSE listed companies. I am a qualified financial expert and can serve on audit, N&G and compensation committees. My background includes taking a company public, raising over $500M privately and publicly, successful M&A transactions and completing multiple large pharma collaboration deals.

Bogart, Georgia, United States

Lanier discovers and develops antibody treatments to restore and improve better health: seeing, breathing, and believing.RetinalBiobetter multifunctional anti-VEGF antibodies.Type 2 InflammationModerate-to-severe conditions, like asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and food allergies, with limited response to corticosteroid treatment.Immuno-OncologyProprietary antibody offerings.MT-6402 in the clinic with Molecular Templates.

Athens, Georgia, United States

Abeome's DiSH technology is the key to driving unprecedented efficiencies in screening for new targets. Using DiSH, desired monoclonals can be identified using fluorescent-labeled antigens to bind surface-expressed antibodies, making isolation and cloning desired cells significantly easier. Abeome is actively looking for partners interested in leveraging the company’s DiSH technology to enable accelerated pre-clinical identification and screening of monoclonal antibody targets. Our strategy encompasses licensing the platform technology to leading pharmaceutical/biotech companies, offering fee-for-service antibody generation, and co-developing our own mAbs for key therapeutic and diagnostic applications. Non-exclusive licenses are available for unlimited access and commercialization of the technology, or by specific fields of interest (i.e., research use only, diagnostics, animal health).

Seattle, Wa

EpiThany, Inc.TM was founded in 2014 in Seattle to consolidate the discovery technology and clinical stage assets of the Tumor Vaccine Group (TVG) and the pioneering work of Dr. Nora Disis. Since identifying the HER-2 tumor antigen in breast cancer in the early 1990’s, Dr. Disis and the TVG have taken their laboratory discoveries into early clinical development. The products under development are multi-epitope DNA vaccines that target multiple antigens overexpressed in cancer for the treatment and prevention of solid tumors. These vaccines are engineered to selectively stimulate inflammatory (Th1) immunity to tumor antigens, without producing the tolerogenic (Th2) immune response that typically arises from self-antigens.The current portfolio of patents licensed from the University of Washington includes two clinical-stage programs, one clinic- ready program in addition to a library of well characterized antigens and epitopes geared toward generating Th1 specific immunity against a variety of human cancers while avoiding stimulating a competitive Th2 response. Delivery of these therapeutics via a straightforward plasmid DNA vector makes them simple to manufacture, store, transport, and administer. Clinical trials have shown them to be well-tolerated with desirable immunogenicity characteristics.

Greater Seattle Area

Greater Seattle Area

Nexgenia develops and manufactures proprietary polymers and polymer-containing magnetic nanoparticles. These unique polymers change state – from soluble single molecules to large macromolecular aggregates – in response to very modest changes of temperature, pH, or salt in their environment. When these polymers are attached to other chemicals / biologicals, they confer the same environmentally-responsive characteristics. Thus the resulting combinations can be small when it is advantageous to be small and large when that facilitates separation and analysis. This property enables the development of faster, more complete molecular / cellular separations and faster, more sensitive immunoassays.The emerging field of personalized immunotherapies, such as CAR T-cell therapies, rely heavily on the ability to separate cells from a patient sample quickly and efficiently. Nexgenia’s polymer-bearing nanoparticles enable antibodies to be utilized at much higher concentrations and to bind with targets much faster. Following target binding, the nanoparticles can be converted within seconds to large size for faster more complete separations leading to faster and more sensitive assays.

Greater Seattle Area

Greater Seattle Area

Scottsdale, Az

Prismic Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company developing highly differentiated proprietary products in two distinct FDA categories, Prescription Drugs and Prescription Medical Foods, based on its two lead pharmaceutically active ingredients, ultra-micronized palmitoylethanolamide, and ultra-pure, high EPA, Omega-3. The company is developing products to address three key therapeutic areas with very large patient populations, and where there are clear and significant unmet clinical needs, namely, chronic kidney disease, depression, and severe chronic pain.

Pasadena, Ca

North Carolina

Greater Seattle Area

Thousand Oaks, Ca

South San Francisco, Ca

San Carlos, Ca

Mba, Finance

M.S., Nutritional Sciences

B.S., Nutritional Sciences

Associate Of Science (A.S.)